EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Assessment of Lectin Staining Biomarkers for GNE Myopathy Gene Therapy

Kristina M Sattler iD, Brian J Paleo iD, Mackenzie N Roth, Kara E Bradley, Megan N Winkler, Wakako Yoshioka iD, Ichizo Nishino iD, Christoph Lepper iD, Kelly E Crowe iD

Muscle & Nerve · 2026

DOI: 10.1002/mus.70404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Kristina M Sattler und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Lectins, Genetic Therapy, Multienzyme Complexes, Distal Myopathies. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Neuromuscular Disease Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims GNE myopathy (GNEM) is a rare, autosomal recessive disorder caused by mutations in the UDP‐N‐acetylglucosamine (GlcNAc) 2‐epimerase/N‐acetylmannosamine (ManNAc) kinase ( GNE ) gene, which encodes a required enzyme for sialic acid (SA) biosynthesis. Reduced SA production is associated with progressive skeletal muscle wasting, but robust molecular biomarkers of SA deficiency and therapeutic restoration remain lacking. As gene therapy for GNEM continues to advance, there is a critical need for biomarkers that enable early, objective assessment of therapeutic response that may precede detectable clinical improvements. Here, we systematically compare a panel of glycan‐binding lectins to identify sensitive and robust biomarkers of SA deficiency and restoration in GNEM.

Methods

We evaluated a panel of glycan‐binding lectins for differential binding under altered sialylation using fluorescent staining and flow cytometry in a GNE‐ deficient cell model, followed by fluorescent lectin staining of skeletal muscle biopsies from GNEM and non‐GNEM patients.

Results

Subterminal lectins SBA, PNA, and VVA showed greater sensitivity to hyposialylation than terminal lectins. By flow cytometry, SBA and PNA increased 90.38‐ and 50.03‐fold, respectively, in GNE ‐deficient cells and decreased 96.06% and 91.83% following GNE restoration. In GNEM muscle, PNA showed the greatest increase (5.3‐fold) and most consistent discrimination from non‐GNEM muscle.

Discussion

PNA demonstrated the most robust and consistent performance across models, supporting its promise as a biomarker to reflect restoration of sialylation that would occur in skeletal muscle after GNEM gene therapy. Further validation in clinical samples will establish its utility as a pharmacodynamic biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LectinsGenetic TherapyMultienzyme ComplexesDistal MyopathiesHumansBiomarkersMuscle, SkeletalN-Acetylneuraminic AcidFemale

Stichwörter der Autor:innen

GNE myopathybiomarkergene therapylectinsialic acid

Substanzen

BiomarkersLectinsMultienzyme ComplexesUDP-N-acetylglucosamine 2-epimerase - N-acetylmannosamine kinaseN-Acetylneuraminic Acid

Autor:innen und Institutionen

  • Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, USA.
  • Dorothy M. Davis Heart and Lung Research Institute, the Ohio State University, Columbus, Ohio, USA.
  • Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.
  • Department of Biology, Mount St. Joseph University, Cincinnati, Ohio, USA.
  • Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan.
  • Division of Physiology and Pathology, College of Osteopathic Medicine, Xavier University, Cincinnati, Ohio, USA.

ORCID-Profile: Kristina M Sattler, Brian J Paleo, Wakako Yoshioka, Ichizo Nishino, Christoph Lepper, Kelly E Crowe

Förderung

  • Neuromuscular Disease Foundation

Zitieren

APA

Sattler, K. M., Paleo, B. J., Roth, M. N., Bradley, K. E., Winkler, M. N., Yoshioka, W., Nishino, I., Lepper, C., & Crowe, K. E. (2026). Assessment of Lectin Staining Biomarkers for GNE Myopathy Gene Therapy. Muscle & Nerve. https://doi.org/10.1002/mus.70404

Vancouver

Sattler KM, Paleo BJ, Roth MN, Bradley KE, Winkler MN, Yoshioka W, et al. Assessment of Lectin Staining Biomarkers for GNE Myopathy Gene Therapy. Muscle & Nerve. 2026. doi:10.1002/mus.70404

BibTeX
@article{Sattler2026,
  author = {Sattler, Kristina M and Paleo, Brian J and Roth, Mackenzie N and Bradley, Kara E and Winkler, Megan N and Yoshioka, Wakako and Nishino, Ichizo and Lepper, Christoph and Crowe, Kelly E},
  title = {Assessment of Lectin Staining Biomarkers for GNE Myopathy Gene Therapy},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70404}
}
Kostenlos starten →